Contribute Try STAT+ Today

A version of this story originally appeared in The Readout, STAT’s biotech newsletter. Sign up here.

Dr. David Hung has had a distinguished career in biotech, presiding over the development of a blockbuster cancer drug and flipping a company for $14 billion. But the last act, in which he led an Alzheimer’s disease startup through a catastrophic failure, is one from which he’d like to move on.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • NELO data will be spectacular
    Its from the ARNA labs
    GPCR technology is 3 for 3 all best in class
    Ralenepig
    Entresimod
    Belviq
    Soon Apd 371 Non opioid pain Non addictive

    He left too soon

  • Jumping on Axovant ship he proved that the first time around he got either unbelievably lucky, or he was just a street smart. Either way, he must be a mediocre scientist/physician.

Comments are closed.